Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Oral semaglutide (Rybelsus) can be tied to a near halving of incident Afib, according to a meta-analysis of 26 randomized ...

For patients newly diagnosed with atrial fibrillation during hospitalization for other causes, most are not dispensed anticoagulants in the year after discharge.

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

A new study published in the Journal of the American College of Cardiology showed that the patients with atrial fibrillation ...

The study was published online in JAMA Neurology on March 31, 2025.

A new draft guideline published today aims to address this widespread variation by recommending a standardised approach to rehabilitation across five major neurological conditions, including brain and ...

Abelacimab is associated with reduced bleeding compared with rivaroxaban in patients with atrial fibrillation (AF ... with use of the direct-acting oral anticoagulant (DOAC) score.

1 Premier Applied Sciences, Premier Inc., Charlotte, NC, United States 2 Bristol-Myers Squibb, Dallas-Fort Worth, TX, United States Background: Non-valvular atrial fibrillation (NVAF ... real-world ...

and sleep apnea — as well as atrial fibrillation itself through anticoagulation and rhythm control.” John Dodson, MD, MPH, director of the Geriatric Cardiology Program at NYU Langone Health ...

Analyses were adjusted for current smoking, stroke risk, comorbidities, years since initial atrial fibrillation diagnosis, use of antiarrhythmic and anticoagulant medications before ablation ...